Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Acta Haematol. 2023;146(5):419-423. doi: 10.1159/000531461. Epub 2023 Jun 20.
Photon counting detector (PCD) computed tomography (CT) is a paradigm-shifting innovation in CT imaging which was recently granted approval for clinical use by the US Food and Drug Administration. PCD-CT allows the generation of multi-energy images with increased contrast and scanning speed or ultra-high spatial resolution (UHR) images with lower radiation doses, compared to the currently used energy integrating detector (EID) CT. Since the recognition of bone disease related to multiple myeloma is important for the diagnosis and management of patients, the advent of PCD-CT heralds a new era in superior diagnostic evaluation of myeloma bone disease. In a first-in-human pilot study, patients with multiple myeloma were imaged with UHR-PCD-CT to validate and establish the utility of this technology in routine imaging and clinical care. We describe 2 cases from that cohort to highlight the superior imaging performance and diagnostic potential of PCD-CT for multiple myeloma compared to clinical standard EID-CT. We also discuss how the advanced imaging capabilities from PCD-CT enhances clinical diagnostics to improve care and overall outcomes for patients.
光子计数探测器（PCD）计算机断层扫描（CT）是 CT 成像领域的一项颠覆性创新，最近已获得美国食品和药物管理局（FDA）的临床使用批准。与目前使用的能量积分探测器（EID）CT 相比，PCD-CT 允许生成具有更高对比度和更快扫描速度的多能量图像，或具有更低辐射剂量的超高空间分辨率（UHR）图像。由于识别与多发性骨髓瘤相关的骨骼疾病对于患者的诊断和治疗非常重要，因此 PCD-CT 的出现标志着骨髓瘤骨骼疾病的卓越诊断评估新时代的到来。在一项首次人体的试点研究中，对多发性骨髓瘤患者进行了 UHR-PCD-CT 成像，以验证和确立该技术在常规成像和临床护理中的实用性。我们从该队列中描述了 2 个病例，以突出与临床标准 EID-CT 相比，PCD-CT 对多发性骨髓瘤的卓越成像性能和诊断潜力。我们还讨论了 PCD-CT 的先进成像功能如何增强临床诊断，以改善患者的护理和整体结果。
